HepaRegeniX
ID: 7645123Small molecule MKK4 inhibitors developer to treat acute and chronic liver diseases.
4
Funding Rounds
$61.6m
Money raised
Recent Funding Rounds
Overview
Small molecule MKK4 inhibitors developer to treat acute and chronic liver diseases.
- Website:
- Headquarters: Tübingen
- Social accounts: linkedin
Unlock Complete Company Intelligence
Access comprehensive data and insights available only to Seedtable members
Financial Details
- • Complete funding history and valuations
- • Revenue estimates and financial metrics
- • Investment round details and terms
People & Contacts
- • Complete leadership team profiles
- • Contact information and email addresses
- • Board members and advisors
Market Intelligence
- • Competitive landscape analysis
- • Market position and growth metrics
- • Industry benchmarking data
Premium Tools
- • Export data and generate reports
- • Save companies to custom watchlists
- • API access for data integration
Join 10,000+ Professionals
Trusted by investors, founders, and analysts worldwide
Access detailed insights on 71,000+ companies worldwide
Funding
Funding series
Funding Series Analysis
The company HepaRegeniX has raised a total of $61.6m in funding over 4 rounds.
Key Insights:
- HepaRegeniX Series C Round, April 2025: $24m
- HepaRegeniX July 2024 Series C Funding Round: $16m
- HepaRegeniX Series B round, January 2020: $12.1m
- HepaRegeniX Series A round, January 2017: $9.5m
Industries
HepaRegeniX is active in the following industries: